2024
Estimating the lives that could be saved by expanded access to weight-loss drugs
Pandey A, Ye Y, Wells C, Singer B, Galvani A. Estimating the lives that could be saved by expanded access to weight-loss drugs. Proceedings Of The National Academy Of Sciences Of The United States Of America 2024, 121: e2412872121. PMID: 39405358, PMCID: PMC11513960, DOI: 10.1073/pnas.2412872121.Peer-Reviewed Original ResearchConceptsGlucagon-like peptide-1Body mass index categoriesObesity prevalence dataGlucagon-like peptide-1 receptor agonistsHazard ratio of mortalityRatio of mortalityPublic health impactWeight loss drugsInsurance coverage issuesGastric inhibitory polypeptideHealthcare accessType 2 diabetesUnited StatesPublic health crisisObesity epidemicReceptor agonistsIndex categoriesHazard ratioPrevalence dataInhibitory polypeptidePeptide-1Health impactsNovel treatmentObesityHealth crisisMortality and morbidity ramifications of proposed retractions in healthcare coverage for the United States
Pandey A, Fitzpatrick M, Singer B, Galvani A. Mortality and morbidity ramifications of proposed retractions in healthcare coverage for the United States. Proceedings Of The National Academy Of Sciences Of The United States Of America 2024, 121: e2321494121. PMID: 38648491, PMCID: PMC11066981, DOI: 10.1073/pnas.2321494121.Peer-Reviewed Original ResearchMeSH KeywordsAgedFemaleHumansInsurance CoverageInsurance, HealthMaleMedicaidMedicareMorbidityMortalityUnited States
2015
The Impact of Enhanced Screening and Treatment on Hepatitis C in the United States
Durham DP, Skrip LA, Bruce RD, Vilarinho S, Elbasha EH, Galvani AP, Townsend JP. The Impact of Enhanced Screening and Treatment on Hepatitis C in the United States. Clinical Infectious Diseases 2015, 62: 298-304. PMID: 26628566, PMCID: PMC4706637, DOI: 10.1093/cid/civ894.Peer-Reviewed Original ResearchConceptsHepatitis C virusInterferon-free DAAsHCV incidenceTreatment ratesChronic hepatitis C virusCases of cirrhosisInjection drug useImpact of administrationAnnual treatment ratesEnhanced screeningHCV prevalenceHCV screeningDecompensated cirrhosisHCV infectionHCV transmissionHepatitis CLiver transplantActing antiviralsLevels of screeningPatients 4C virusHepatocellular carcinomaEpidemiological dataUniversal screeningDrug use
2009
Optimizing Influenza Vaccine Distribution
Medlock J, Galvani AP. Optimizing Influenza Vaccine Distribution. Science 2009, 325: 1705-1708. PMID: 19696313, DOI: 10.1126/science.1175570.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAge FactorsAgedCenters for Disease Control and Prevention, U.S.ChildChild, PreschoolDisease OutbreaksHealth PolicyHumansImmunization ProgramsInfantInfluenza A virusInfluenza A Virus, H1N1 SubtypeInfluenza VaccinesInfluenza, HumanMiddle AgedModels, StatisticalUnited StatesVaccinationYoung AdultConceptsOutcome measuresNovel swine-origin influenzaOptimal vaccine allocationInfluenza vaccine distributionContingent valuationSwine-origin influenzaYears of lifePublic health policyOptimal allocationEconomic costsInfluenza vaccineSeasonal influenzaInfluenza pandemicU.S. CentersVaccine allocationDisease controlMortality dataVaccine distributionHealth policyOptimal vaccinationPolicy optimizationTransmission dynamicsInfluenzaAllocationNew recommendations